Small Molecule Drug Restores Survival in Mouse Model of Rare Kidney Disorder Primary Hyperoxaluria Type 2

Researchers at the Buck Institute for Research on Aging have identified a small molecule drug candidate that completely restored survival in a lethal mouse model of Primary Hyperoxaluria Type 2 (PH2), a rare genetic disorder linked to progressive kidney failure. The orally administered compound, N-propargylglycine (N-PPG), demonstrated significant therapeutic potential in preclinical studies. PH2 currently has no existing treatment options, making this discovery particularly noteworthy.

The study focused on addressing the severe impact of PH2, which primarily affects infants and young adults by causing excessive oxalate buildup that leads to kidney stone formation and eventual organ failure. Researchers tested N-PPG in mice genetically engineered to mimic the disease’s progression. Results showed that the compound effectively mitigated symptoms and restored survival rates in the animal models. This development marks a significant step forward in understanding and potentially treating PH2, offering hope for future clinical applications aimed at combating this devastating condition.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 2, 2026

Author

GOAI